Screener
BioMarin Pharmaceuticals BMRN Net product revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| REVENUES: | ||||
| Net product revenues | $984,393 | $812,982 | $1,744,471 | $1,547,626 |
| Royalty and other revenues | 5,315 | 12,428 | 11,445 | 22,929 |
| Total revenues | 989,708 | 825,410 | 1,755,916 | 1,570,555 |
| OPERATING EXPENSES: | ||||
| Cost of sales | 202,795 | 150,090 | 397,794 | 301,648 |
| Research and development | 206,952 | 161,308 | 385,748 | 320,039 |
| Selling, general and administrative | 395,549 | 232,279 | 653,839 | 438,395 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's net product revenues — total revenues?
- BioMarin Pharmaceuticals (BMRN) reported net product revenues — total revenues of $984.39M in Q2 2026.
- How has BioMarin Pharmaceuticals's net product revenues — total revenues changed year-over-year?
- BioMarin Pharmaceuticals's net product revenues — total revenues increased by 21.1% year-over-year, from $812.98M to $984.39M.
- What is the long-term trend for BioMarin Pharmaceuticals's net product revenues — total revenues?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's net product revenues — total revenues has grown at a 15.4% compound annual growth rate (CAGR), from $1.78B to $3.17B.
- What does net product revenues — total revenues mean?
- This metric represents the total revenue generated from the sale of pharmaceutical products after accounting for returns, rebates, and discounts. It serves as the primary indicator of the company's commercial success in marketing its portfolio of rare-disease therapies. This figure reflects the core operational performance of the business excluding licensing or collaboration income.
Ask your AI about BioMarin Pharmaceuticals's net product revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude